Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Howard, Andrea A.; Hirsch-Moverman, Yael; Frederix, Koen; Daftary, Amrita; Saito, Suzue; Gross, Tal; Wu, Yingfeng; Maama, Llang Bridget (2016)
Publisher: Co-Action Publishing
Journal: Global Health Action
Languages: English
Types: Article
Subjects: Global Health, TB/HIV integration; implementation science; cost-effectiveness; acceptability; TB treatment success, RC306-320.5
Background: Initiating antiretroviral therapy (ART) early during tuberculosis (TB) treatment increases survival; however, implementation is suboptimal. Implementation science studies are needed to identify interventions to address this evidence-to-program gap.Objective: The Start TB Patients on ART and Retain on Treatment (START) Study is a mixed-methods, cluster-randomized trial aimed at evaluating the effectiveness, cost-effectiveness, and acceptability of a combination intervention package (CIP) to improve early ART initiation, retention, and TB treatment success among TB/HIV patients in Berea District, Lesotho.Design: Twelve health facilities were randomized to receive the CIP or standard of care after stratification by facility type (hospital or health center). The CIP includes nurse training and mentorship, using a clinical algorithm; transport reimbursement and health education by village health workers (VHW) for patients and treatment supporters; and adherence support using text messaging and VHW. Routine data were abstracted for all newly registered TB/HIV patients; anticipated sample size was 1,200 individuals. A measurement cohort of TB/HIV patients initiating ART was recruited; the target enrollment was 384 individuals, each to be followed for the duration of TB treatment (6–9 months). Inclusion criteria were HIV-infected; on TB treatment; initiated ART within 2 months of TB treatment initiation; age ≥18; English- or Sesotho-speaking; and capable of informed consent. The exclusion criterion was multidrug-resistant TB. Three groups of key informants were recruited from intervention clinics: early ART initiators; non/late ART initiators; and health care workers. Primary outcomes include ART initiation, retention, and TB treatment success. Secondary outcomes include time to ART initiation, adherence, change in CD4+ count, sputum smear conversion, cost-effectiveness, and acceptability. Follow-up and data abstraction are complete.Discussion: The START Study evaluates a CIP targeting barriers to early ART implementation among TB/HIV patients. If the CIP is found effective and acceptable, this study has the potential to inform care for TB/HIV patients in high-burden, resource-limited countries in sub-Saharan Africa.Keywords: TB/HIV integration; implementation science; cost-effectiveness; acceptability; TB treatment success(Published: 27 June 2017) Citation: Glob Health Action 2016, 9: 31543 - http://dx.doi.org/10.3402/gha.v9.31543Supplementary material: To access the supplementary material for this article, please see Supplementary files under ‘Article Tools’
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. World Health Organization (2015). Global tuberculosis control 2015. Geneva: WHO.
    • 2. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143 52.
    • 3. Harries AD, Zachariah R, Corbett EL, Lawn SD, SantosFilho ET, Chimzizi R, et al. The HIV-associated tuberculosis epidemic when will we act? Lancet 2010; 375: 1906 19.
    • 4. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resourcelimited settings. Clin Chest Med 2009; 30: 685 99, viii.
    • 5. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605 12.
    • 6. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492 501.
    • 7. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471 81.
    • 8. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482 91.
    • 9. World Health Organization (2010). Treatment of tuberculosis: guidelines. 4th ed. Geneva: WHO.
    • 10. Huerga H, Spillane H, Guerrero W, Odongo A, Varaine F. Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya. Int J Tuberc Lung Dis 2010; 14: 611 15.
    • 11. Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R, et al. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infect Dis 2011; 11: 258.
    • 12. Murphy RA, Sunpath H, Taha B, Kappagoda S, Maphasa KT, Kuritzkes DR, et al. Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010; 14: 903 8.
    • 13. Njozing NB, Miguel SS, Tih PM, Hurtig AK. Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. BMC Public Health 2010; 10: 129.
    • 14. van Lettow M, Chan AK, Ginsburg AS, Tweya H, Gareta D, Njala J, et al. Timing and uptake of ART during treatment for active tuberculosis in HIV co-infected adults in Malawi. Public Health Action 2011; 1: 6 9.
    • 15. Zachariah R, Harries AD, Manzi M, Gomani P, Teck R, Phillips M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS One 2006; 1: e121.
    • 16. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008 2013. J Acquir Immune Defic Syndr 2015; 69: 98 108.
    • 17. Dong K, Thabethe Z, Hurtado R, Sibaya T, Dlwati H, Walker B, et al. Challenges to the success of HIV and tuberculosis care and treatment in the public health sector in South Africa. J Infect Dis 2007; 196(Suppl 3): S491 6.
    • 18. Gandhi NR, Moll AP, Lalloo U, Pawinski R, Zeller K, Moodley P, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009; 50: 37 43.
    • 19. Chileshe M, Bond VA. Barriers and outcomes: TB patients coinfected with HIV accessing antiretroviral therapy in rural Zambia. AIDS Care 2010; 22(Suppl 1): 51 9.
    • 20. Harris JB, Hatwiinda SM, Randels KM, Chi BH, Kancheya NG, Jham MA, et al. Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia. Int J Tuberc Lung Dis 2008; 12: 773 9.
    • 21. Kumwenda M, Tom S, Chan AK, Mwinjiwa E, Sodhi S, Joshua M, et al. Reasons for accepting or refusing HIV services among tuberculosis patients at a TB-HIV integration clinic in Malawi. Int J Tuberc Lung Dis 2011; 15: 1663 9.
    • 22. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011; 24: 34 42.
    • 23. Okot-Chono R, Mugisha F, Adatu F, Madraa E, Dlodlo R, Fujiwara P. Health system barriers affecting the implementation of collaborative TB-HIV services in Uganda. Int J Tuberc Lung Dis 2009; 13: 955 61.
    • 24. Padian NS, Holmes CB, McCoy SI, Lyerla R, Bouey PD, Goosby EP. Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR). J Acquir Immune Defic Syndr 2011; 56: 199 203.
    • 25. Joint United States Programme on HIV/AIDS (2014). The GAP report. Geneva: UNAIDS.
    • 26. World Health Organization (2013). Global tuberculosis control 2013. Geneva: WHO.
    • 27. The World Bank. Data: Lesotho. 2016. Available from: http:// data.worldbank.org/country/lesotho [cited 20 January 2016].
    • 28. Glasgow RE, Eckstein ET, Elzarrad MK. Implementation science perspectives and opportunities for HIV/AIDS research: integrating science, practice, and policy. J Acquir Immune Defic Syndr 2013; 63(Suppl 1): S26 31.
    • 29. Lesotho Ministry of Health. Kingdom of Lesotho. National Tuberculosis Programme Policy and Manual. Maseru: Lesotho Ministry of Health; 2007.
    • 30. Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks, CA: Sage; 2002.
    • 31. Sandelowski M. Sample size in qualitative research. Res Nurs Health 1995; 18: 179 83.
    • 32. Ministry of Health and Social Welfare (Lesotho), ICF Macro (2010). Lesotho demographic and health survey 2009. Maseru, Lesotho: MOHSW.
    • 33. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606 13.
    • 34. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction 1993; 88: 791 804.
    • 35. Reynolds WM. Development of reliable and valid short forms of the Marlowe-Crowne Social Desirability Scale. J Clin Psychol 1982; 38: 119 25.
    • 36. Wilson IB, Fowler FJ, Jr, Cosenza CA, Michaud J, Bentkover J, Rana A, et al. Cognitive and field testing of a new set of medication adherence self-report items for HIV care. AIDS Behav 2014; 18: 2349 58.
    • 37. Kalichman SC, Amaral CM, Stearns H, White D, Flanagan J, Pope H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007; 22: 1003 6.
    • 38. Rubin HJ, Rubin IS. Qualitative interviewing: the art of hearing data. 2nd ed. Thousand Oaks, CA: Sage; 2004.
    • 39. Durlak JA, DuPre EP. Implementation matters: a review of research on the influence of implementation on program outcomes and the factors affecting implementation. Am J Community Psychol 2008; 41: 327 50.
    • 40. World Health Organization (2004). Compendium of indicators for monitoring and evaluating national tuberculosis programs. Geneva: WHO.
    • 41. Seale C, Gobo G, Gubrium JF, Silverman D. Qualitative research practice. Thousand Oaks, CA: Sage; 2004.
    • 42. World Health Organization (2011). Global tuberculosis control 2011. Geneva: WHO.
    • 43. Murray DM, Varnell SP, Blitstein JL. Design and analysis of group-randomized trials: a review of recent methodological developments. Am J Public Health 2004; 94: 423 32.
    • 44. Corbin JM, Strauss A. Grounded theory research: procedures, canons, and evaluative criteria. Qual Sociol 1990; 13: 3 21.
    • 45. Patton MQ. Enhancing the quality and credibility of qualitative analysis. Health Serv Res (5Pt 2) 1999; 34: 1189 208.
    • 46. United States Agency for International Development. ADS chapter 579: USAID development data. Available from: https:// www.usaid.gov/ads/policy/500/579 [cited 6 May 2016].
    • 47. Duflo E, Kremer M. Use of randomization in the evaluation of development effectiveness. World Bank Operations Evaluation Department Conference on Evaluation and Development Effectiveness, 2003. Available from: http://people.bu.edu/jgerring/ Conference/MethodsGovernance/documents/DufloKremerpro grameval.pdf [cited 30 January 2011].
    • 48. Creswell JW, Plano-Clark VL. Designing and conducting mixed methods research. Los Angeles, CA: Sage; 2011.
    • 49. Greene JC, Caracelli VJ, Graham WF. Toward a conceptual framework for mixed-method evaluation designs. Educ Eval Policy Anal 1989; 11: 255 74.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from